Genetic discoveries as the basis of personalized therapy: rosiglitazone treatment of Alzheimer's disease. (Q53279548)

12 May 2018

title

Genetic discoveries as the basis of personalized therapy: rosiglitazone treatment of Alzheimer's disease. (English)

1 reference

12 May 2018

1 reference

Hsueh W

1

1 reference

12 May 2018

publication date

1 July 2006

1 reference

12 May 2018

The Pharmacogenomics Journal

published in

1 reference

12 May 2018

volume

6

1 reference

12 May 2018

issue

4

1 reference

12 May 2018

page(s)

222-224

1 reference

12 May 2018

https://scigraph.springernature.com/pub.10.1038/sj.tpj.6500383

exact match

0 references

cites work

Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Insulin and neurodegenerative disease: shared and specific mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Insulin increases CSF Abeta42 levels in normal older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Muscle-specific Pparg deletion causes insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Cloning of adiponectin receptors that mediate antidiabetic metabolic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

The gene defects responsible for familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Imaging beta-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Amyloid peptides are toxic via a common oxidative mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Thiol reducing compounds prevent human amylin-evoked cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3'-kinase-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Response of experimental retinal neovascularization to thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Translational research on the way to effective therapy for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500383

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.TPJ.6500383

1 reference

12 May 2018

PubMed ID

16865098

1 reference

12 May 2018